Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01388478 · ClinicalTrials.gov registry record · Phase 2
Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01388478 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 20 participants.
The verdict
NCT01388478, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
By doing this study, researchers will examine the safety and tolerability of R-pramipexole in participants with Alzheimer's disease. This study will also examine the body and brain's response to the study drug by measuring the amount of injury to the cells (oxidative stress) in the blood and spinal fluid and brain imaging before and after treatment.
Interventions
- DRUG R-pramipexole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01388478
The ClinicalTrials.gov registry entry for NCT01388478 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which R-pramipexole is the first listed.
NCT01388478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01388478 about?
NCT01388478 is a clinical study titled "Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease". By doing this study, researchers will examine the safety and tolerability of R-pramipexole in participants with Alzheimer's disease. This study will also examine the body and brain's response to the study drug by measuring the amount of injury to the cells (oxidative stress) in the blood and spinal ...
What is the current status of trial NCT01388478?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-07. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01388478?
The interventions under investigation include: R-pramipexole (DRUG).
Who is sponsoring clinical trial NCT01388478?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.